Xilio Therapeutics, Inc. (XLO) Stock: Dividends & Earnings

Company Overview:

Market Cap: $59.71M

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $6.47 - $12.58

5 Year XLO Performance Metrics:

Total Return (with DRIP): -95.9% (-47.33% CAGR)

Total Return (no DRIP): -95.9% (-47.33% CAGR)

Share Price: -95.9% (-47.33% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $405

Total Return $ (with DRIP): -$9,595

XLO Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

XLO Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

Projected Future Returns & Dividends for XLO

Based on past 5-year performance, here are XLO growth metrics:

Share price CAGR of -47.33%
Dividend CAGR of +0%

Using XLO CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	XLO (DRIP)	XLO - No DRIP
Current Price	$9.08	$9.08
Start Shares	1,101.32	1,101.32
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	1,101.32	1,101.32
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$0.01	$9.08
Total Dividends	$0	$0
Final Value	$16	$10,000

Estimated Future Value + Dividends - XLO

NOTE: Above numbers are our estimate based on XLO's Dividend and Price CAGR over past 5 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

Company Info

Xilio Therapeutics, Inc. (XLO) had its IPO on , and is traded on NASDAQ stock exchange.

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for cancer. Its current portfolio centers on tumor-activated biologics designed to localize immune activity within the tumor microenvironment while aiming to reduce systemic side effects associated with broader immunotherapies. The company’s pipeline includes investigational checkpoint inhibitors, cytokines, and immune-cell engaging therapies, with programs spanning solid tumors and other cancer settings. Xilio Therapeutics also uses its proprietary platform to engineer tumor-selective molecules such as antibodies and cytokine-based candidates, which are intended to support more precise immune responses. Based in Waltham, Massachusetts, Xilio Therapeutics plays a role in advancing next-generation oncology treatments across the biotechnology and pharmaceutical markets.

XLO website: https://xiliotx.com